Juvenile elastic arteries after 28 years of renal replacement therapy in a patient with complete complement C4 deficiency

Florian Knoll\(^{1\ast}\), Emanuel Zitt\(^{1,3}\), Denis Intemann\(^{2}\) and Karl Lhotta\(^{1,3}\)

Abstract

**Background:** Complement activation products are present in atherosclerotic plaques. Recently, binding of complement to elastin and collagen in the aortic wall has been demonstrated, suggesting a role of complement in the development aortic stiffness and atherosclerosis. The definitive role of complement in atherosclerosis and arteriosclerosis, however, remains unclear.

**Case presentation:** We here describe a patient with hereditary complete deficiency of complement C4 suffering from Henoch-Schoenlein purpura and on renal replacement therapy for twenty-eight years. The patient had the full range of risk factors for vascular damage such as hypertension, volume overload, hyperphosphatemia and hyperparathyroidism. Despite that, his carotid artery intima media thickness was below the normal range and his pulse wave velocity was normal. In contrast, the patient’s coronary and peripheral muscular arteries were heavily calcified.

**Conclusion:** This case supports the hypothesis that complement plays an important role in the development of stiffness of elastic arteries. We speculate that inability to activate complement by the classical or lectin pathways protected the patient from atherosclerosis, arteriosclerosis, stiffening and calcification of the aorta and carotid arteries. Inhibition of complement activation may be a potential target for prophylactic and therapeutic interventions.

**Keywords:** Complement, Atherosclerosis, Arteriosclerosis, Renal replacement therapy

**Background**

Accelerated vascular calcification and vascular stiffening are common in end-stage renal disease (ESRD) [1-3]. Both are associated with mortality in the CKD and ESRD population [4]. No effective therapeutic strategy is available to prevent or slow down vascular calcification and arterial stiffening in patients with chronic kidney disease. It has recently been shown that complement components C3 and C4 bind to elastic and collagen fibers in the mouse aorta, and it was postulated that complement may play a central role in progressive vascular stiffening of elastic arteries [5]. We here describe a patient who, despite having multiple risk factors, does not show any signs of arteriosclerosis or atherosclerosis of his central elastic arteries after 28 years of renal replacement therapy. This unexpected finding is potentially related to the primary disease of the patient: hereditary complete deficiency of complement component C4.

**Case presentation**

**Clinical history**

The patient suffered from Henoch-Schoenlein purpura with severe renal involvement from the age of seventeen. From 1984 to 1985, aged 23 years, he underwent hemodialysis treatment. In 1985, he received his first renal allograft. Transplant function deteriorated because of interstitial fibrosis/tubular atrophy and recurrence of his primary disease. Immunofluorescence of the biopsies of the patient’s own kidneys and the transplant showed granular deposits of IgG, IgM, IgA and C3 in the mesangium and along the glomerular capillary walls. Staining for...
C4 was negative [6]. From 1989 to 1997 he again underwent hemodialysis. In 1996 a total parathyroidectomy with autotransplantation into the right brachioradial muscle was performed for severe hyperparathyroidism with a PTH of 820 pg/ml, hypercalcemia and hyperphosphatemia. After surgery PTH levels remained between 50 and 100 pg/ml. In 1997, a second renal transplantation was performed. In 2006, allograft function deteriorated and a transplant biopsy revealed advanced calcineurin inhibitor-associated arteriolopathy. Hyperphosphatemia despite treatment with various phosphate binders and a tendency to hypercalcemia were present during the years with reduced transplant function since 2006. Despite advanced renal failure, marked hypertension due to extensive fluid overload and despite severe hyperphosphatemia the patient refused to initiate dialysis until July 2011. Table 1 shows laboratory values and medications at commencement of dialysis.

**Investigation of arterial vessels**

At age 51 the patient underwent ultrasound of the carotid arteries as part of pre-transplant evaluation for a third kidney transplantation. Figure 1 shows the structure of the wall of both common carotid arteries to be completely normal without atherosclerotic plaques. The carotid artery intima-media thickness (CIMT) was 0.44 mm for the right common carotid artery (CCA) and 0.50 mm for the left CCA, thus on both sides clearly below the upper limit of 0.71 mm for a healthy population of the same age [7]. In addition, we assessed aortic augmentation index (Figure 2) and carotid-femoral pulse-wave velocity (PWV) using the SphygmoCor™ system (AtCor Medical, Sydney, Australia). The patient’s PWV of 5.3 ± 0.1 m/s is expected in a healthy adolescent, but is highly unusual in a patient who has been on renal replacement therapy for almost three decades. As a mean PWV a reference value of 11.6 ± 3.3 m/s has been proposed for patients with CKD 5 [8]. We did not detect signs of aortic calcification in thorax x-rays and in ultrasound investigations of the abdominal aorta and no signs of valvular calcifications in an echocardiography.

X-ray examinations of the patient’s hands and right foot (Figure 3) for joint pain revealed advanced calcification of the anterior and posterior tibial and plantar arteries and the radial artery, a finding to be expected in a patient with long-lasting kidney disease. Duplex ultrasound examination of peripheral muscular arteries (Figure 4) confirmed the presence of abundant vessel wall calcifications. The arterial blood flow signal was normal without signs of vascular stenosis. Computed tomography of the coronary arteries revealed severe calcification with an Agatston score of 782.5 corresponding to the 99th percentile of age and gender matched controls [9]. Co-illustrated slices of the aorta were free of calcification.

**Complement C4 deficiency**

The patient’s primary disease is hereditary complete deficiency of complement C4, and C4 was never detected in his serum on multiple occasions. The human complement C4 genes are located on chromosome 6 in the major histocompatibility complex region. They encode for two highly polymorphic isoforms, C4A and C4B. Hereditary complete C4 deficiency is exceptionally rare with less than 30 patients having been reported. Most of them suffered from a lupus-like illness. Our patient is homozygous for the MHC haplotype HLA A30 B18 DR7. This haplotype does not contain C4A genes, but instead two mutant short C4B genes with a 8127 g → a point mutation at the donor site of the intron 28 splice junction, which abrogates correct RNA splicing [10]. Splicing according to a new potential donor site seven nucleotides downstream would lead to a stop codon in exon 29. These results and the absence of C4 from our patient’s serum strongly suggest that he was completely C4-deficient.

| Table 1 Laboratory values and medication before the patient started hemodialysis 2011 |
|---------------------------------------------|------------------|---------------------|----------------------|
| Parameter       | Value         | Medication          | Daily dose           |
| Creatinine      | 8.1 mg/dl    | Sodium bicarbonate  | 1 g                  |
| Urea            | 310 mg/dl    | Calcium carbonate   | 3 g                  |
| Calcium         | 2.42 mmol/l  | Lanthanum carbonate | 2250 mg              |
| Phosphate       | 2.55 mmol/l  | Sevelamer carbonate | 7.2 g                |
| PTH             | 103 pg/ml    | Furosemide          | 500 mg               |
| Haemoglobin     | 104 g/l      | Moxonidine          | 0.2 mg               |
| Triglycerides   | 93 mg/dl     | Metoprolol          | 95 mg                |
| Cholesterol     | 157 mg/dl    | Amlodipine          | 10 mg                |
| HDL-cholesterol | 81 mg/dl     | Darbepoietin        | 40 μg once weekly    |
| LDL             | 72 mg/dl     |                     |                      |
Discussion

Arteriosclerosis of central and peripheral arteries is the hallmark of the vasculopathy of chronic kidney disease. In addition to traditional risk factors, CKD-specific factors such as electrolyte abnormalities seem to drive vascular pathology in these patients. Our patient with almost 30 years of renal replacement therapy does not fit into this scheme. As expected, his coronary and peripheral muscular arteries were heavily calcified. He had, however, well preserved central elastic arteries.

It is highly unusual to find completely normal carotid vessels without intimal hyperplasia or atherosclerotic plaques and without calcification of the media in a patient who has been on renal replacement therapy for so long, including ten years of hemodialysis. The finding of a PWV of 5.2 m/s corresponds to the PWV of a young adult without arteriosclerosis of the aorta and is also unexpected [11]. He had suffered from the whole array of conditions that are thought to cause the vasculopathy of chronic kidney disease. The efficacy of these mechanisms is clearly illustrated by the calcifications of coronary and peripheral vessels. We believe that the patient’s primary disease, complement C4 deficiency, can explain these unusual findings.

C4 and atherosclerosis

How might C4 deficiency protect against atherosclerosis? C4 is a main component of the classical and lectin pathways of complement. Without doubt, complement plays a role in the development of atherosclerosis. Terminal complement complex C5b-9 is regularly detected in atherosclerotic lesions [12]. In animal models, C6 deficiency protects against plaque formation [13]. Classical pathway activation may occur by several mechanisms in atherosclerosis. C-reactive protein, also present in lesions, is a potent activator of the classical pathway [14]. In addition, activation can be triggered by immune complexes containing autoantibodies against oxidized LDL and heat shock proteins [15].
Even more intriguing is the total absence of arteriosclerosis of central elastic arteries in this patient with C4 deficiency. Recent studies in mice support a role of complement in arteriosclerosis of these vessels [5]. It has been shown that complement components C3 and C4 are deposited along collagen and elastin fibers in the external elastic lamina of the aorta. These complement components are most likely derived from the perivascular adipose tissue of the aorta. Complement deposition increases with age and parallels vascular stiffening. In atherosclerosis-prone ApE(−/−) mice complement deposition extends into the media and intimal plaques. How C3 and C4 are deposited along collagen and elastin remains unclear. Spontaneously hydrolyzed C3 and C4 may attach covalently to the fibers. Alternatively, fibromodulin and adiponectin, which bind to collagen fibers in vessel walls [16,17], also bind to C1q and activate the classical complement pathway [18,19], which then would lead to complement deposition. As C4 is the central component of the classical pathway, the findings in our patient with C4 deficiency would favor the second mechanism and suggest that complement deposition in the vessel wall is mediated by the classical or lectin pathway. How complement activation eventually leads to vascular stiffening and calcification, remains to be determined. Complement fragments may attract leucocytes to the vascular wall, where they may be activated by complement and secrete proinflammatory cytokines. Elevated levels of interleukin-6 and tumor necrosis factor-alpha in the circulation are associated with vascular calcification in patients with chronic kidney disease [20]. They are also associated with low levels of fetuin-a, a potent inhibitor of calcification [21]. Complement activation may create a local environment in the vessel wall that strongly favors calcification. In an animal model of diabetes collagen synthesis and ventricular stiffening in the heart have been shown to be dependent on mannos-binding lectin and activation of the lectin pathway [22]. Likewise, a complement C5a receptor antagonist prevented cellular infiltration, fibrosis and stiffening of the heart in DOCA-salt hypertensive rats [23]. In analogy, complement activation may also accelerate fibrosis and stiffening of the central elastic vessels. Recently C4d deposits in the adventitia have been found in 50% of patients undergoing surgery of the ascending aorta. Lack of C4d staining was associated with aortic dissection. Whether complement may have a protective role against aortic dissection remains speculative [24].

Conclusion
Our observations – normal central arteries but advanced calcification of coronary and muscular arteries - also would imply that arteriosclerosis of central elastic and peripheral muscular arteries (including coronary arteries) are driven by separate mechanisms. Whereas arteriosclerosis seems to be complement-dependent in elastic arteries, the process might be complement-independent in muscular arteries. Clearly, further research is needed to unravel the role of the complement system in atherosclerosis and arteriosclerosis. In addition, inhibition of complement
activation may be a potential target for prophylactic and therapeutic interventions.

Consent
The patient gave written informed consent to publication of his case history and all figures.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
All authors are involved in the clinical management of the patient. FK, EZ and KL contributed to drafting and writing of the manuscript. DZ performed ultrasound studies. EZ did the pulse wave velocity investigation and performed ultrasound studies. All authors read and approved the final manuscript.

Author details
1. Department of Nephrology and Dialysis, Feldkirch Academic Teaching Hospital, Canisiusgasse 47, Feldkirch 6800, Austria. 2. Department of Internal Medicine, Academic Teaching Hospital Feldkirch, Feldkirch, Austria. 3. Vorarlberg Institute for Vascular Investigation and Treatment, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.

Received: 7 August 2012 Accepted: 27 November 2012 Published: 2 December 2012

References
1. Goodman WG, Goldin J, Kuzson BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478–1483.
2. Zoungas S, Cameron JD, Kerr PG, Wolfe R, Muske C, McNeil JJ, McGrath BP: Association of carotid intima-media thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD. Am J Kidney Dis 2007, 50:622–630.
3. Guerin AP, London GM, Marchais SJ, Metivier F: Complement proteins C3 and C5. Nephron 2000, 86:279–289.
4. Sigrist MR, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffness and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007, 2:1241–1248.
5. Shields KJ, Stolz D, Watkins SC, Ahearn JM: Complement components C3 and C4 bind to collagen and elastin in the vascular wall: a potential role in vascular stiffness and atherosclerosis. Clin Transl Sci 2011, 4:146–152.
6. Lhotta K, Konig P, Hintner H, Spielberger M, Dittrich P: Renal disease in a cardiovascular complications. J Cardiovasc Pharmacol 2008, 52:104–113.
7. Lim TK, Lim E, Dwivedi G, Koerner J, Senior R: Normal value of carotid intima-media thickness—a surrogate marker of atherosclerosis: quantitative assessment by 8-mode carotid ultrasound. J Am Soc Echocardiogr 2008, 21:112–116.
8. Wang MC, Taal WC, Chen JY, Huang JJ: Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005, 45:494–501.
9. McClelland RS, Chung H, Detrano R, Post W, Kronmal RA: Distribution of coronary artery calcium by race, gender, and age: results from the multi-ethnic study of atherosclerosis (MESA). Circulation 2006, 113:30–37.
10. Yang Y, Lhotta K, Chung EK, Eder P, Neumair F, Yu CY: Complete complement components C4A and C4B deficiencies in human kidney diseases and systemic lupus erythematosus. J Immunol 2004, 173:2893–2894.
11. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson J, Struijker-Boudier H: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588–2605.
12. Niculescu F, Hugo F, Rus HG, Vlaciu R, Bhalki S: Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. Clin Exp Immunol 1987, 69:477–483.

13. Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, Oleert H, Metz J, Bhalki S: Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998, 18:1790–1795.
14. Paffen E, DeMaest MT: C-reactive protein in atherosclerosis: a causal factor? Cardiovasc Res 2006, 71:30–39.
15. Burat DF, Karim Y, Feins GA: The role of immune complexes in atherogenesis. Angiology 2010, 61:679–689.
16. Strom A, Ahlqvist E, Franzen A, Heinegard D, Hultgardh-Nilsson A: Extracellular matrix components in atherosclerotic arteries of Apo E/IDL receptor deficient mice: an immunohistochemical study. Histol Histopathol 2004, 19:337–347.
17. Okamoto Y, Arta Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, Iguira T, Inui Y, Kihara S, Nakamura T, et al: An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000, 32:47–50.
18. Sjoberg A, Onnerfjord P, Morgenf M, Heinegard D, Blom AM: The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem 2005, 280:32301–32308.
19. Peake PW, Shen Y, Walther A, Charlesworth JA: Adiponectin binds C1q and activates the classical pathway of complement. Biochem Biophys Res Commun 2008, 367:560–565.
20. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecotis-Filho R, Reila M, Heimbürger O, Cederholm T, Gimmler M, IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 2005, 67:1216–1233.
21. Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C: Serum fetuin-A concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine 2008, 44:323–327.
22. Pavlov VI, La Bonte LR, Baldwin WM, Markiewski MM, Lambris JD, Stahl GL: Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol 2012, 180:104–112.
23. Iyer A, Woodruff TM, Wu MC, Stylianou C, Reid RC, Fairlie DP, Taylor SM, Brown L: Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2011, 58:479–486.
24. Ninimaki E, Paavonen T, Valo T, Tarkka M, Mennander A: Lack of C4d deposition may reveal susceptibility for ascending aortic dissection. Scand Cardiovasc J 2012, 46:177–182.

doi:10.1186/1471-2369-13-161
Cite this article as: Knoll et al.: Juvenile elastic arteries after 28 years of renal replacement therapy in a patient with complete complement C4 deficiency. BMC Nephrology 2012 13:161.